<DOC>
	<DOCNO>NCT00002596</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It know whether combine chemotherapy bone marrow peripheral stem cell transplantation effective combination chemotherapy alone treat men germ cell tumor . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy without bone marrow peripheral stem cell transplantation treat men previously untreated germ cell tumor .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Bone Marrow Stem Cell Transplantation Treating Men With Untreated Germ Cell Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy bleomycin , etoposide , cisplatin ( BEP ) without high-dose carboplatin , etoposide , cyclophosphamide plus autologous bone marrow peripheral blood stem cell transplantation male patient poor- intermediate-risk germ cell tumor . - Compare toxicity regimens patient . - Compare prospectively prognosis term rate decline serum tumor marker , human chorionic gonadotropin ( hCG ) alpha-fetoprotein ( AFP ) , patient treat regimen . - Correlate hCG AFP complete response survival patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center risk status ( poor v intermediate ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive bleomycin IV day 1 , 8 , 15 etoposide ( VP-16 ) IV 30-60 minute cisplatin ( CDDP ) IV 30-60 minute day 1-5 ( BEP ) . Filgrastim ( G-CSF ) administer subcutaneously ( SC ) day 7-16 blood count recover . Treatment continue every 3 week 4 course absence disease progression unacceptable toxicity . G-CSF discontinue 24 hour initiate subsequent course chemotherapy , withheld day bleomycin administration . - Arm II : Patients receive 2 course BEP G-CSF arm I . Patients marrow involvement tumor undergo harvest autologous bone marrow first second course BEP . Patients bone marrow involvement tumor undergo harvest G-CSF-mobilized autologous peripheral blood stem cell ( PBSC ) day 17-21 first and/or second course BEP . When blood count recover , patient receive high-dose intensification comprise carboplatin IV 1 hour , VP-16 IV 30-60 minute , cyclophosphamide IV 1 hour day -5 -3 . Autologous bone marrow PBSC reinfused 15-20 minute day 0 . G-CSF administer SC begin 24 hour transplantation continue blood count recover . Beginning 1-3 week hospital discharge first transplantation recovery toxic effect , patient Karnofsky performance status 70-100 % receive second course high-dose intensification plus second bone marrow PBSC transplantation absence disease progression unacceptable toxicity . Patients arm brain metastasis presentation undergo radiotherapy and/or surgery concurrently BEP , medically indicate . Patients normal alpha fetoprotein ( AFP ) human chorionic gonadotropin ( hCG ) tumor marker level completion treatment arm I II undergo surgical resection residual mass . Patients residual malignant tumor undergo complete resection mature teratoma receive therapy . Patients arm I undergo complete resection residual malignant tumor receive 2 additional course VP-16 CDDP without bleomycin . Patients arm II undergo complete resection residual malignant tumor receive additional chemotherapy . Patients unresectable residual malignant tumor receive additional therapy discretion treat physician . Patients residual tumor marker ( AFP hCG ) positivity treatment arm I II undergo resection residual mass tumor marker value fall normal marker half-life . PROJECTED ACCRUAL : A total 270 patient ( 135 per treatment arm ) accrue study within 4.4 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven poorrisk , nonseminoma germ cell tumor Must meet 1 follow 3 condition : Testis retroperitoneal primary site without visceral metastasis follow tumor marker value : Lactic dehydrogenase ( LDH ) great 10 time upper limit normal ( ULN ) Human chorionic gonadotropin ( hCG ) great 50,000 IU/L Alphafetoprotein ( AFP ) great 10,000 ng/mL Testis retroperitoneal primary site 1 nonpulmonary visceral metastasis ( regardless tumor marker value ) , include follow : Bone Brain Liver Other nonpulmonary viscera ( e.g. , skin , spleen ) Mediastinal primary site , regardless presence/absence visceral metastasis tumor marker value OR Histologically proven intermediaterisk , nonseminoma germ cell tumor Testis retroperitoneal primary site visceral metastasis ( except lung ) , follow tumor marker value : LDH 310 time ULN hCG 5,00050,000 IU/L AFP 1,00010,000 ng/mL OR Histologically proven intermediaterisk , seminoma germ cell tumor 1 nonpulmonary visceral metastasis ( regardless tumor marker value primary site ) , include follow : Bone Brain Liver Other nonpulmonary visceral metastasis ( e.g. , skin , spleen ) Histologic confirmation may delay , discretion protocol chairman , initiation study therapy patient testicular mass elevate AFP hCG medical circumstance warrant immediate treatment Measurable evaluable disease Concurrent registration protocol MSKCC89076 ( SWOG9345 ) tumor biology study require PATIENT CHARACTERISTICS : Age : 12 Sex : Male Performance status : Not specify Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : See Disease Characteristics Renal : Creatinine great ULN* OR Creatinine clearance great 50 mL/min* NOTE : * Abnormal level due ureteral obstruction tumor allow discretion protocol chairman Other : HIV negative No concurrent malignancy except nonmelanomatous skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 30 day since prior radiotherapy except brain metastasis document disease progression Recovered toxic effect prior radiotherapy Surgery : Recovered effect recent surgery</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2003</verification_date>
	<keyword>stage II malignant testicular germ cell tumor</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>testicular seminoma</keyword>
	<keyword>testicular embryonal carcinoma</keyword>
	<keyword>testicular choriocarcinoma</keyword>
	<keyword>testicular teratoma</keyword>
	<keyword>testicular yolk sac tumor</keyword>
	<keyword>testicular embryonal carcinoma teratoma</keyword>
	<keyword>testicular embryonal carcinoma teratoma seminoma</keyword>
	<keyword>testicular embryonal carcinoma yolk sac tumor</keyword>
	<keyword>testicular embryonal carcinoma yolk sac tumor seminoma</keyword>
	<keyword>testicular embryonal carcinoma seminoma</keyword>
	<keyword>testicular yolk sac tumor teratoma</keyword>
	<keyword>testicular yolk sac tumor teratoma seminoma</keyword>
	<keyword>testicular choriocarcinoma yolk sac tumor</keyword>
	<keyword>testicular choriocarcinoma embryonal carcinoma</keyword>
	<keyword>testicular choriocarcinoma teratoma</keyword>
	<keyword>testicular choriocarcinoma seminoma</keyword>
	<keyword>extragonadal germ cell tumor</keyword>
	<keyword>childhood teratoma</keyword>
	<keyword>childhood malignant testicular germ cell tumor</keyword>
	<keyword>childhood extragonadal germ cell tumor</keyword>
</DOC>